US Pharma MarketingDetecting meaningful change in rare disease trials requires more than statistics—it demands the right COA. Discover why sensitivity matters and how AI is transforming trial outcomes.
Measuring what matters: New priorities in COA selection
Detecting meaningful change in rare disease trials requires more than statistics—it demands the right COA. Discover why sensitivity matters and how AI is transforming trial outcomes.
Source: BioPharma Dive